Stockscreener 앱 받기
105.46
0.09%
-0.10
시간 외 거래:
106.19
0.73
+0.69%
전일 마감가:
$105.56
열려 있는:
$106.28
하루 거래량:
540.18K
Relative Volume:
0.48
시가총액:
$26.67B
수익:
$3.32B
순이익/손실:
$-1.26B
주가수익비율:
-20.16
EPS:
-5.2311
순현금흐름:
$289.80M
1주 성능:
+2.47%
1개월 성능:
+21.48%
6개월 성능:
-0.19%
1년 성능:
-12.51%
1일 변동 폭
$104.51
$106.92
1주일 범위
$102.10
$113.26
52주 변동 폭
$79.52
$124.00
바이오앤테크 Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
105.46 | 26.67B | 3.32B | -1.26B | 289.80M | -5.2311 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-06-05 | 재확인 | H.C. Wainwright | Buy |
| 2025-05-29 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
Sierk Poetting Sells 50,000 Shares of BioNTech (NASDAQ:BNTX) Stock - MarketBeat
Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor - GlobeNewswire Inc.
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
BioNTech's Oncology Pipeline Delivers Critical Data as Strategic Pivot Accelerates () - aktiencheck.de
BNTX Earnings History & Surprises | EPS & Revenue Results | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch - TipRanks
Lbp Am Sa Acquires 15,255 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Impfung: Between Pandemic Legacy and Oncology Pivot, Future Hinges on Pipeline Wins - AD HOC NEWS
BioNTech SE Sponsored ADR $BNTX Shares Sold by Baillie Gifford & Co. - MarketBeat
Net income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech SE Sponsored ADR Revenue Breakdown – BSESOF:22UA - TradingView
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID - TipRanks
Operating income of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView — Track All Markets
BioNTech's Shareholder Vote to Cement Post-Pandemic Strategy () - aktiencheck.de
Why Is Pfizer Stock Dropping Tuesday? - Sahm
European ADRs Slipped As Biotech Lagged And UK Names Rose - Finimize
Leerink cuts BioNTech stock price target on drug trial concerns - Investing.com
BioNTech Shifts Strategy with Dual Operational Pullbacks () - aktiencheck.de
BioNTech's Strategic Pivot: Fueling Oncology Ambition with Capital Reserves () - aktiencheck.de
BioNTech Shares Navigate Dual Challenges Amid Strategic Shift () - aktiencheck.de
BioNTech announces invitation to 2026 annual general meeting for May 15 - Investing.com
BioNTech's mRNA Vaccine Platform: Current Developments and Strategic Importance for North American I - AD HOC NEWS
HC Wainwright Issues Negative Estimate for BioNTech Earnings - MarketBeat
BioNTech (NASDAQ:BNTX) Given New $130.00 Price Target at HC Wainwright - Defense World
BioNTech SE (STU:22UA) Stock Price, Trades & News - GuruFocus
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know - MSN
BNTX Stock Today: March 31: ELCC Cancer Data Steady Amid Biotech Rout - Meyka
BioNTech at a Crossroads: Financial Pressures and Clinical Promise Collide () - aktiencheck.de
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Short Interest Down 20.7% in March - MarketBeat
BioNTech's Oncology Pipeline Shows Promise with Significant Survival Data () - aktiencheck.de
BioNTech SE Sponsored ADR Trade Ideas — BSESOF:22UA - TradingView
Total equity of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
EBITDA per share of BioNTech SE Sponsored ADR – BSESOF:22UA - TradingView
BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next - TipRanks
BioNTech SE Sponsored ADR $BNTX Shares Bought by SG Americas Securities LLC - MarketBeat
BioNTech (NASDAQ:BNTX) Receives Buy Rating from Jefferies Financial Group - defenseworld.net
BioNTech stock plunges as founders leave. Should you buy the dip in BNTX here? - MSN
BioNTech Oncology Pipeline Shows Promising Survival Data in Late-Stage Lung Cancer Trials as of Marc - AD HOC NEWS
AKT I: „ICI VARSOVIE” [c66293] - Fathom Journal
BioNTech Faces Leadership Transition Amid Pivotal Clinical Milestones () - aktiencheck.de
BioNTech's Oncology Pivot Accelerates Amid Leadership Transition and €17B Cash Reserve - AD HOC NEWS
Hudson Bay Capital Management LP Acquires 55,004 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Stock Forecast | Co-Founders Plan Departure - Capital.com
Groupama Asset Managment Trims Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech (NASDAQ:BNTX) Given “Buy” Rating at Deutsche Bank Aktiengesellschaft - Defense World
Long Focus Capital Management LLC Has $39.22 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.61%
6.02%
자본화:
|
볼륨(24시간):